Karachi: The Searle Company Limited ne apne FY24 earnings aur future outlook par corporate briefing conduct ki. Yahan kuch important highlights hain:
- Earnings Update: SEARL ka consolidated topline Rs29bn tak pohanch gaya, jo 14% YoY ka izafa hai. Gross margin mein ~3ppts ka improvement hui, jo 46.6% tak hai. Magar, company ne Rs2.4bn ka loss report kiya hai, jo ke subsidiary ke discontinued operations ka Rs3.8bn loss ki wajah se hua.
- Therapeutic Brands: SEARL ke top brands mein Hydrllin, Nuberol, Peditral, Extor, Rotec, Gravinate, aur Venofer shamil hain.
- Drug Price Hike: Non-essential medicines ki deregulation ke baad, company ne prices increase ki hain, jis ka kuch impact topline mein reflect hua hai. SEARL ke portfolio ka 80% non-essential drugs par mabni hai.
- Local Innovation: SEARL ne Pakistan mein locally manufactured monoclonal antibody ‘ADALIMUMAB’ launch ki hai, jo filhal local market mein kisi competition ka samna nahi kar rahi. Agle 12-18 months mein is category ke aur products bhi launch hone ki umeed hai.
- Upcoming Product Launch: SEARL semaglutide launch karne ki tayari kar raha hai. Machines procure ki ja rahi hain, aur yeh drug agle saal ke beech tak available hogi.
- Export Markets: SEARL apne products Uzbekistan aur Azerbaijan mein register karwa raha hai. Saath hi GCC region mein facility register ho chuki hai, jo year-end tak operational ho jayegi.
- Subsidiary Divestment Plan: Management SPL subsidiary ke divestment transaction ko current year ke end tak complete karna chahti hai. Debt reduction aur product portfolio expansion ke liye in receipts ka istemal hoga.
Yeh briefing SEARL ke agle projects aur expansion plans ka wazeh roadmap dete hain.
